SR-717
SR-717 Basic information
- Product Name:
- SR-717
- Synonyms:
-
- SR-717
- SR171
- SR-717 lithium
- SR 717 (lithium salt)
- immunity,MPYS,MITA,inhibit,ISG-THP1,Inhibitor,SR 717,mimetic,TMEM173,STING,SR717,cGAMP,THP1,antitumor,ERIS,SR-717,PD-L1,Stimulator of Interferon Genes
- Lithium 2-(6-(1H-imidazol-1-yl)pyridazine-3-carboxamido)-4,5-difluorobenzoate
- SR171&SR-717 lithium
- SR-717, 10 mM in DMSO
- CAS:
- 2375421-09-1
- MF:
- C15H10F2LiN5O3
- MW:
- 353.21
- Mol File:
- 2375421-09-1.mol
SR-717 Chemical Properties
- storage temp.
- Inert atmosphere,Room Temperature
- solubility
- Soluble in DMSO (>25 mg/ml)
- form
- solid
- color
- Off-white
- Water Solubility
- Water: < 0.1 mg/mL (insoluble)
- Stability:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month1.
- InChI
- InChI=1S/C15H9F2N5O3.Li.H/c16-9-5-8(15(24)25)12(6-10(9)17)19-14(23)11-1-2-13(21-20-11)22-4-3-18-7-22;;/h1-7H,(H,19,23)(H,24,25);;
- InChIKey
- FTILLHFNTUUQIF-UHFFFAOYSA-N
- SMILES
- N(C1C=C(F)C(F)=CC=1C(=O)O)C(C1N=NC(N2C=NC=C2)=CC=1)=O.[LiH]
SR-717 Usage And Synthesis
Description
SR-717 (2375421-09-1) is a cell permeable and exceptionally selective STING agonist (IC50 = 7.8 μM).? It displayed robust antitumor activity in B16.F10 melanoma and MC38 colorectal adenocarcinoma mouse models. SR-717 promoted the activation of CD8+ T, natural killer, and dendritic cells as well as promoting antigen cross-priming. It was able to induce PD-L1 expression in THP1 cells and in primary human PBMC’s.
Uses
SR-717 is a non-nucleotide STING agonist with EC50s of 2.1 μM and 2.2 μM in ISG-THP1 (WT) and ISG-THP1 cGAS KO (cGAS KO) cell lines, respectively. SR-717 is a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic. Antitumor activity[1].
in vivo
SR-717 (30 mg/kg intraperitoneal once-per-day for 1 week) shows antitumor activities in WT or Stinggt/gt mice[1].
SR-717 (30 mg/kg intraperitoneally for 7 days) displays antitumor activity; promots the activation of CD8+ T, natural killer, and dendritic cells in relevant tissues; and facilitates antigen cross-priming[1].
| Animal Model: | WT or Stinggt/gt mice[1] |
| Dosage: | 30 mg/kg |
| Administration: | Intraperitoneally; once-per-day for 1 week |
| Result: | Maximally inhibited tumor growth. |
References
[1] EMILY N. CHIN. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic[J]. Science, 2020, 369 6506. DOI:10.1126/science.abb4255
SR-717Supplier
- Tel
- 17721492509; 17721492509
- 643638326@qq.com
- Tel
- 18515581800 18501085097
- sales.bj@hwrkchemical.com
- Tel
- 0371-55932928 18937192232
- 1282296214@qq.com
- Tel
- 021-52996696,15000506266 15000506266
- Tel
- 021-65675885 18964387627
- info@efebio.com
SR-717(2375421-09-1)Related Product Information
- 4-Quinolinecarboxamide, N-[3-[[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]carbonyl]phenyl]-1,2-dihydro-2-oxo-
- NA
- SRT3025
- SR9009
- SR19881
- SRPK inhibitor
- SR 1078
- N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide
- SRI 31215
- SR 0987
- SR27897
- SR17018
- SR-9243
- SR 3029
- SR 16832
- SR8278
- SR-4835
- SR18662